The dilutive offering at a discount signals urgent cash needs despite positive FDA regulatory progress. Monitor the Q3 2026 NDA submission for CNM-Au8 and subsequent FDA acceptance, which could provide a near-term catalyst. The 60-day lock-up for insiders reduces overhang risk in the near term, but further cash burns may require additional financing.
Price Chart
Executive Summary
Clene Inc. is offering 1,000,000 shares of common stock at $7.00 per share, a 13.5% discount to the $8.09 closing price on May 4, 2026. The offering raises approximately $6.4 million in net proceeds to fund NDA preparation for ALS drug CNM-Au8 and general corporate purposes. The company faces a going concern with only $5.2M cash at year-end 2025, ongoing losses, and substantial dilution (~8.5%) for existing shareholders.
Key Facts
- Offering 1,000,000 shares at $7.00 per share, raising ~$7M gross / ~$6.4M net
- Discount of ~13.5% to May 4 close of $8.09
- Going concern: cash and equivalents only $5.2M as of Dec 31, 2025; operating loss $23.1M in 2025
- Accumulated deficit $308.3M; no approved drugs; revenue from dietary supplements only
- FDA agreed on May 4 that data may support accelerated NDA submission in Q3 2026 for ALS
- Pro forma share count increases from 11.8M to 12.8M, diluting existing holders by ~8.5%
- Insiders sold $768K in past 30 days ahead of offering
Financial Impact
Public offering of 1,000,000 shares at $7.00/share raises ~$7M gross (~$6.4M net). Immediate dilution of ~8.5% to existing shareholders. Pro forma net tangible book value deficit improves from -$1.62 to -$0.94 per share, but investors face $7.94 per share dilution.
Risk Factors
- Substantial doubt about going concern; cash runway likely less than 12 months
- Dilution from this and potential future offerings
- FDA accelerated approval for ALS is uncertain; NDA may not be accepted or approved
- High cash burn rate with no product revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001437749-26-014937 |
| Document: 0001437749-26-014937-index-headers.html | 0001437749-26-014937 |
| Document: 0001437749-26-014937-index.html | 0001437749-26-014937 |
| Document: 0001437749-26-014937.txt | 0001437749-26-014937 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $3.73 | awaiting T+20 | — | $3.97 (+6.43%) |
Oct 19, 2026 8d ago | 8-K | $3.29 | awaiting T+20 | — | $3.97 (+20.67%) |
Oct 19, 2026 8d ago | Press Release | $3.29 | awaiting T+20 | — | $3.97 (+20.67%) |
Oct 13, 2026 14d ago | SC 13G/A | $3.39 | awaiting T+20 | — | $3.97 (+17.11%) |
Sep 16, 2026 5w ago | 8-K | $4.15 $3.31 | ▲ +20.36% | ▲ +21.57% | $3.97 (+4.34%) |
Sep 16, 2026 5w ago | 424B5 | $3.86 $3.31 | ▲ +14.25% | ▲ +16.31% | $3.97 (−2.85%) |
Aug 14, 2026 10w ago | 8-K | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.97 (−4.11%) |
Aug 14, 2026 10w ago | Press Release | $4.14 $3.28 | ▼ −20.77% | ▼ −18.78% | $3.97 (−4.11%) |
Aug 10, 2026 11w ago | 8-K | $5.16 $3.62 | ▼ −29.84% | ▼ −28.93% | $3.97 (−23.06%) |
May 14, 2026 23w ago | 8-K | $7.05 $5.84 | ▼ −17.16% | ▼ −16.30% | $3.97 (−43.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers